WO2004052280A3 - Anti-angiogenic compounds and their use in cancer treatment - Google Patents

Anti-angiogenic compounds and their use in cancer treatment Download PDF

Info

Publication number
WO2004052280A3
WO2004052280A3 PCT/US2003/038512 US0338512W WO2004052280A3 WO 2004052280 A3 WO2004052280 A3 WO 2004052280A3 US 0338512 W US0338512 W US 0338512W WO 2004052280 A3 WO2004052280 A3 WO 2004052280A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
cancer treatment
angiogenic compounds
methods
dependent diseases
Prior art date
Application number
PCT/US2003/038512
Other languages
French (fr)
Other versions
WO2004052280A2 (en
Inventor
Evgueni Piatnitski
Alexander Kiselyov
Jacqueline Doody
Yaron Hadari
Shawn Ouyang
Xiaoling Chen
Original Assignee
Imclone Systems Inc
Evgueni Piatnitski
Alexander Kiselyov
Jacqueline Doody
Yaron Hadari
Shawn Ouyang
Xiaoling Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc, Evgueni Piatnitski, Alexander Kiselyov, Jacqueline Doody, Yaron Hadari, Shawn Ouyang, Xiaoling Chen filed Critical Imclone Systems Inc
Priority to AU2003293376A priority Critical patent/AU2003293376A1/en
Publication of WO2004052280A2 publication Critical patent/WO2004052280A2/en
Publication of WO2004052280A3 publication Critical patent/WO2004052280A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Compounds that inhibit angiogenesis and are useful in the treatment of angiogenic dependent diseases like cancer are disclosed as well as pharmaceutical compositions that contain such compounds, methods of treating angiogenic dependent diseases and conditions in mammals using such compounds and methods of producing the compounds and compositions.
PCT/US2003/038512 2002-12-10 2003-12-05 Anti-angiogenic compounds and their use in cancer treatment WO2004052280A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003293376A AU2003293376A1 (en) 2002-12-10 2003-12-05 Anti-angiogenic compounds and their use in cancer treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43200702P 2002-12-10 2002-12-10
US60/432,007 2002-12-10
US72649603A 2003-12-04 2003-12-04
US10/726,496 2003-12-04

Publications (2)

Publication Number Publication Date
WO2004052280A2 WO2004052280A2 (en) 2004-06-24
WO2004052280A3 true WO2004052280A3 (en) 2004-08-12

Family

ID=32511622

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/038512 WO2004052280A2 (en) 2002-12-10 2003-12-05 Anti-angiogenic compounds and their use in cancer treatment

Country Status (2)

Country Link
AU (1) AU2003293376A1 (en)
WO (1) WO2004052280A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7283699B2 (en) 2017-05-12 2023-05-30 マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Phenyl-heterocycle-phenyl derivative for use in treating or preventing melanoma

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP4617299B2 (en) * 2003-03-03 2011-01-19 アレイ バイオファーマ、インコーポレイテッド p38 inhibitors and methods of use thereof
US7932272B2 (en) 2003-09-30 2011-04-26 Eisai R&D Management Co., Ltd. Antifungal agent containing heterocyclic compound
CN101039933B (en) * 2004-09-17 2012-06-06 沃泰克斯药物股份有限公司 Diaminotriazole compounds useful as protein kinase inhibitors
KR101318012B1 (en) * 2004-10-20 2013-10-14 메르크 세로노 에스.에이. 3-arylamino pyridine derivatives
DE102004055998A1 (en) * 2004-11-19 2006-05-24 Rheinische Friedrich-Wilhelms-Universität Bonn Low molecular weight inhibitors of guanine nucleotide exchange factors of the cytohesin family
WO2006064375A2 (en) * 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
US7829585B2 (en) 2005-03-30 2010-11-09 Eisai R&D Management Co., Ltd. Antifungal agent containing pyridine derivative
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
TWI385169B (en) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd Heterocyclic substituted pyridine derivatives and antifungal agent containing same
JP5131990B2 (en) 2006-01-31 2013-01-30 アレイ バイオファーマ、インコーポレイテッド Kinase inhibitors and methods of use thereof
WO2007123939A2 (en) * 2006-04-19 2007-11-01 Laboratoires Serono S.A. Novel arylamino n-heteraryls as mek inhibitors
EA200802050A1 (en) * 2006-04-19 2009-04-28 Лаборатуар Сероно Са NEW HETEROARYLIC-SUBSTITUTED ARYLAMINOPIRIDINE DERIVATIVES AS MEK INHIBITORS
WO2007149395A2 (en) * 2006-06-20 2007-12-27 Amphora Discovery Corporation 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer
US8183264B2 (en) 2006-09-21 2012-05-22 Eisai R&D Managment Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
JP5284788B2 (en) * 2006-09-21 2013-09-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 Heteroaryl ring-substituted pyridine derivatives and antifungal agents containing them
US8236823B2 (en) 2006-10-27 2012-08-07 Amgen Inc. Multi-cyclic compounds and methods of use
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
AU2007329480A1 (en) * 2006-12-05 2008-06-12 National Chio Tung University Indazole compounds
DE102007002717A1 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclic indazole derivatives
CA2676163A1 (en) 2007-01-29 2008-08-07 Santen Pharmaceutical Co., Ltd. Novel oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
DE102007022565A1 (en) 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclic indazole derivatives
EP2053046A1 (en) 2007-10-26 2009-04-29 Syngeta Participations AG Novel imidazole derivatives
EP2053045A1 (en) 2007-10-26 2009-04-29 Syngenta Participations AG Novel imidazole derivatives
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
GB0806745D0 (en) * 2008-04-14 2008-05-14 Syngenta Participations Ag Novel imidazole derivatives
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
ES2927660T3 (en) 2008-06-16 2022-11-10 Univ Tennessee Res Found Compounds for the treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
DE102008038221A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-azaindole derivatives
DE102008038220A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh oxadiazole
DE102008038222A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carboxylic acid derivatives
US8188119B2 (en) 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
KR20120130777A (en) * 2010-03-01 2012-12-03 유니버시티 오브 테네시 리서치 파운데이션 Compounds for treatment of cancer
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
JP6456909B2 (en) 2013-03-15 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ LXR regulator
WO2014181287A1 (en) * 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
MX2016014559A (en) 2014-05-06 2018-02-19 Gtx Inc Compounds for treatment of cancer.
WO2017047602A1 (en) * 2015-09-18 2017-03-23 科研製薬株式会社 Biaryl derivative and medicine containing same
IT201600092051A1 (en) * 2016-09-13 2018-03-13 Alessandro Antonelli MEDICAL COMPOUND FOR TREATMENT OF THYROID CANCER
JP6469272B2 (en) * 2017-03-01 2019-02-13 科研製薬株式会社 A pharmaceutical comprising a biaryl derivative or a salt thereof
WO2018204532A1 (en) * 2017-05-03 2018-11-08 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
CN112457306A (en) * 2019-09-06 2021-03-09 上海瑛派药业有限公司 3, 5-disubstituted pyrazole compounds as kinase inhibitors and application thereof
EP4061364A4 (en) * 2019-11-20 2023-09-13 Vivace Therapeutics, Inc. Heteroaryl compounds
US20230089180A1 (en) * 2021-08-13 2023-03-23 Bisichem Co., Ltd. Fused ring heteroaryl compounds and use thereof
CN114044774B (en) * 2021-12-06 2024-04-09 光武惠文生物科技(北京)有限公司 EGFR inhibitor and preparation method and application thereof
CN116041277A (en) * 2023-01-18 2023-05-02 中国药科大学 Phenyl and biphenyl substituted five-membered heterocyclic compound, preparation method, pharmaceutical composition and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5438066A (en) * 1992-11-04 1995-08-01 Zeneca Limited Oxa- and thiadiazole derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5438066A (en) * 1992-11-04 1995-08-01 Zeneca Limited Oxa- and thiadiazole derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7283699B2 (en) 2017-05-12 2023-05-30 マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Phenyl-heterocycle-phenyl derivative for use in treating or preventing melanoma

Also Published As

Publication number Publication date
WO2004052280A2 (en) 2004-06-24
AU2003293376A1 (en) 2004-06-30
AU2003293376A8 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
WO2004052280A3 (en) Anti-angiogenic compounds and their use in cancer treatment
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
AU2003254038A1 (en) Glyconjugates comprising carbohydrate epitopes, methods for theirsynthesis, and their use for the treatment or prophylaxis of cancer
MXPA04001876A (en) Use of fucans in the treatment of adhesions, arthritis and psoriasis.
TW200510416A (en) P38 inhibitors and methods of use thereof
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
WO2001087306A8 (en) Compositions and methods for the treatment of colorectal cancer
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
WO2004071382A3 (en) Substituted heterocycles
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2004009072A3 (en) Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
WO2005016883A3 (en) Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
WO2000066528A3 (en) Quinones for treatment of diseases
WO2006102375A3 (en) Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer
WO2004043379A3 (en) Chemical compounds
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
EP1551388A4 (en) Compounds useful for the treatment of cancer, compositions thereof and methods therewith
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP